Bioline Rx Ltd Ord (BLNEF)

Bioline Rx Ltd was incorporated in April 2003. It is a clinical stage biopharmaceutical development company, engaged in identifying, in-licensing and developing therapeutic candidates that have advantages over currently available therapies or that address unmet medical needs. The Company's development pipeline consists of six clinical-stage therapeutic candidates: BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction, or AMI; BL-8040, a novel peptide for the treatment of acute myeloid leukemia (AML), stem cell mobilization and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a customized, proprietary, pen-like applicator containing a novel formulation of two acids, which is being developed in Europe as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease, or IBD; and BL-8020, an orally available treatment for the hepatitis C virus, or HCV, and other viral indications, with a unique mechanism of action involving the inhibition of virus-induced autophagy in host cells. The Company has three therapeutic candidates in the preclinical stages of development. The first therapeutic candidate, BL-1040, is a novel, resorbable polymer solution for use in the reduction or prevention of ventricular remodeling in patients who suffered an AMI. The second clinical-stage therapeutic candidate, BL-8040, is a novel, short peptide that functions as a high-affinity antagonist for CXCR4 used to develop for AML, stem cell mobilization and other hematological indications. The third clinical-stage therapeutic candidate, BL-7010, is a novel, non-absorbable, orally available, high-molecular-weight co-polymer used for the treatment of celiac disease.